Feb 24, 2026Senolytics and Cellular Senescence: Mechanisms, Mayo Clinic Evidence, and Clinical StatusSenolytics are drugs and compounds that selectively clear senescent cells, which accumulate with age and drive chronic inflammation. This review covers the mechanisms, the Mayo Clinic dasatinib+quercetin trials, fisetin evidence, and the current clinical status.
Feb 19, 2026Fisetin and Senolytic Research: Human Data, Protocol Context, and LimitationsFisetin has a strong preclinical senolytic rationale, while human evidence remains early-stage with limited placebo-controlled outcome data.
Feb 18, 2026Dasatinib and Quercetin for Senolytic Therapy: Mayo Clinic Phase 2 Trial FindingsA Mayo Clinic Phase 2 trial tested dasatinib plus quercetin in 60 older women with low bone density, finding improved bone formation markers. Dasatinib is an FDA-approved cancer drug requiring physician supervision.
Feb 14, 2026Supplement Cycling Protocols: Rapamycin, Senolytics, and Adaptogens — Evidence for Intermittent UseNot all supplements should be taken daily. Rapamycin is typically dosed weekly to preserve mTOR signaling windows. Senolytics (dasatinib + quercetin, fisetin) are used in short intermittent bursts. Even some adaptogens are cycled to prevent tolerance. This article maps the rationale and evidence for each.
Feb 8, 2026Dasatinib + Quercetin Senolytic Protocol: Intermittent Dosing, Safety, and Clinical Trial EvidenceThe dasatinib + quercetin (D+Q) combination is the most clinically studied senolytic protocol. Mayo Clinic trials show clearance of senescent cells and functional improvements. Dasatinib is a chemotherapy drug with significant side effects — this is not a casual intervention.
Feb 6, 2026Cellular Senescence: What Zombie Cells Are, Senolytics, and the Evidence TimelineSenescent cells — sometimes called zombie cells — accumulate with age, secreting inflammatory signals (SASP) that damage neighboring tissue. Senolytics selectively eliminate them. This explainer covers the biology, the Mayo Clinic trials, and the current state of senolytic supplements and drugs.
Feb 3, 2026Fisetin as a Senolytic: Zombie Cell Clearance, Mayo Clinic Data, and Dosing EvidenceFisetin is the most potent natural senolytic identified in preclinical studies. The Mayo Clinic demonstrated senescent cell clearance in human adipose tissue. Clinical protocols use intermittent high-dose cycles. Human evidence is early but promising.
Feb 1, 2026Rapamycin and mTOR: Longevity Mechanism, PEARL Trial, and Low-Dose Protocol RisksRapamycin extends lifespan in every organism tested and the PEARL trial is the first human RCT for longevity use. mTOR inhibition reduces cellular senescence and improves immune function. Off-label use carries real risks that must be understood before consideration.